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Abstract
Hematologic malignancies are the most common type of cancer affecting children and young adults, and encompass 
diseases, such as leukemia, lymphoma, and myeloma, all of which impact blood associated tissues such as the bone 
marrow, lymphatic system, and blood cells. Clinical diagnostics of these malignancies relies heavily on the use of bone 
marrow samples, which is painful, debilitating, and not free from risks for leukemia patients. Liquid biopsies are based on 
minimally invasive assessment of markers in the blood (and other fluids) and have the potential to improve the efficacy 
of diagnostic/therapeutic strategies in leukemia patients, providing a useful tool for the real time molecular profiling of 
patients. The most promising noninvasive biomarkers are circulating tumor cells, circulating tumor DNA, microRNAs, 
and exosomes. Herein, we discuss the role of assessing these circulating biomarkers for the understanding of tumor 
progression and metastasis, tumor progression dynamics through treatment and for follow-up.
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INTRODUCTION
Hematologic malignancies, characterized as affecting the bone marrow, lymphatic system, and blood 
cells, are the most common kind of cancer among children and young adults. Leukemia, lymphoma, 
and myeloma are amongst the most frequent presentations within this group of blood related disorders[1]. 
Throughout the sequential stages of hematopoietic differentiation, there are plenty of occasions for 
disruptive biomolecular events to occur (e.g., mutations) that will then promote and/or result in dissimilar 
cancer subtypes and clinical presentations[2].
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Leukemia may be defined as a cancer that derives from the bone marrow and affects hematopoiesis[3]. 
This malignancy results from an abnormal proliferation of white blood cells in the bone marrow, which 
then affects the normal development of cells, and may even spread to other organs such as the spleen, 
the liver, the meninges, lymph nodes, etc.[4]. Because of the wide variability of white blood cells in the 
human body, leukemia differs greatly from other types of cancers and may affect people of all ages, from 
young children to the elderly. In addition, unlike most cancers, population characteristics, such as age, 
race, and lifestyle, do not exempt from being at risk. Leukemias account for over 50,000 new cancer 
cases annually[5]. Leukemia is generally divided into two types, depending on how quickly the immature 
cells (blasts) proliferate: (1) acute leukemia; or (2) chronic leukemia[6]. Leukemia can be further grouped 
considering the cell lineage affected either myeloid or lymphoid. As such, leukemias may be grouped into 
acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), 
and chronic lymphocytic leukemia (CLL)[7-11]. Myelodysplastic syndromes (MDS) constitute a particular 
cohort of hematopoietic myeloid stem cell conditions that has not been completely recognized as such and, 
sometimes, lack full characterization. However, MDS show strong features of hematologic malignancies 
with major impact on the patients’ quality of life[12,13]. Herein, we focus on liquid biopsies (LB) within the 
scope of AML, CML, and MDS.
Myeloid leukemia 
AML 
Similar to other malignant hematopoietic diseases, AML results from an accumulation of immature 
myeloid blast cells in the bone marrow that often extends to the circulating blood[14,15]. However, AML may 
also affect other tissues, such as the skin (leukemia cutis). AML is a severe life-threatening disease that 
may arise in all ages but is more common in the elderly with a median age at diagnosis of approximately 
70 years[16,17]. AML presentation is highly heterogeneous and individual cases are characterized by a wide 
variety of cytogenetic and molecular defects. For instance, the French-American-British classification 
proposes that AML should be classified according to a particular score (M0-M7) according morphological 
and cytochemical criteria[18,19]. For example, about 41% of AML patients have a normal karyotype, but 
several chromosomal translocations have been described, such as t (15; 17) (q22; q21) in 13% of patients; t (8; 
21) (q22; q22) in 7% of reported cases; and inv (16) (p13; q22)/t (16; 16) (p13; q22) in 5% of cases[18]. Some of 
these chromosomal alterations lead to the expression of abnormal fusion proteins with oncogenic potential, 
or to the inactivation of tumor suppressor genes[20]. It should be noted that AML with normal cytogenetics 
is very heterogeneous in its clinical and molecular features, and its pathogenesis is much less clear than 
that of AML with chromosomal rearrangements. Two of the most frequent such rearrangements occur in 
two well-known genes, namely NPM1 (nucleophosmin protein, NPM1) and FLT3 (fms-like tyrosine kinase 
3 protein, FLT3), whose mutational status support prognostics in the clinical assessment[21]. 
CML
CML is a rare malignant proliferative disease of the hematopoietic system with a worldwide incidence 
of 10-12 new cases per 100,000 habitants per year[22]. The molecular hallmark of CML is the Philadelphia 
chromosome (Ph) that originates from the reciprocal translocation t (9; 22) (q34; q11), between the 
breakpoint cluster region (BCR) and the Abelson tyrosine kinase (ABL), which produces a fusion gene 
BCR-ABL[23]. This gene yields the BCR-ABL oncoprotein, a constitutively activated tyrosine kinase, capable 
of recruiting and activating several pathways regulating the transduction of intracellular signals, and 
ultimately resulting in abnormal cellular adhesion, enhanced proliferation, and inhibition of apoptosis[24,25]. 
Disease progression begins by a chronic phase (3-6 years), an accelerated phase follows characterized 
by clonal transformation. Ultimately, a short terminal blast phase occurs[26,27]. One of the first chemical 
compounds to be used against CML was Arsenic, which was later replaced by X-ray irradiation of the 
spleen[28]. During the early 1970s, the use of busulfan and hydroxyurea for the treatment of CML, which 
greatly improved the quality of life during the chronic phase of CML, but without preventing or delaying 
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progression to advanced accelerated phase and blast phase[29]. In the late 1970s and early 1980s, bone 
marrow transplantation (allogeneic hematopoietic stem cell transplantation, allo-HSCT) was introduced 
that allowed completely eradicating the Ph positive cells in the bone marrow and, thus, provided a cure 
for CML patients[30-32]. In 1983, Interferon alpha (IFNa) was reported to significantly reduce the number of 
white blood cells and induce a cytogenetic response in some CML patients[33]. However, the gold standard 
in CML treatment began with the discovery of Tyrosine Kinase Inhibitors (TIs), which selectively block 
the activity of the fusion oncoprotein, radically changing the way clinicians approach this disease. The first 
TKI used in CML therapy was imatinib, which functions as a competitive inhibitor binding to the ATP 
pocket in the kinase domain, with response rates of over 95%[34,35]. Second and third generations of TKIs, 
such as dasatinib, nilotinib, bosutinib, and ponatinib, have subsequently been introduced, improving the 
efficiency of CML chemotherapy[36]. 
MDS
With a yearly incidence of 4:100,000 (prevalence 7:100,000), MDS constitute a group of extremely 
frequent hematological malignancies, characterized by disruption of the bone marrow stroma, with poor 
differentiation and maturation. The incidence of MDS rises sharply with age, reaching 50:100,000/year 
above 80 years of age[37,38]. However, the median age at onset is around 70 years, with only 10% of MDS 
diagnosed patients under the age of 50[37-41]. There is an important clinical criterion for MDS diagnosis that 
is a constant cytopenia for more than three months (other conditions that may cause cytopenia must have 
been excluded), which is usually accompanied by a reduction of blood cell counts. These patients show an 
increased risk (20%-25%) of developing AML[41,42]. For accurate MDS clinical diagnosis, several features 
are considered: (1) dysplasia in more than 10% of cells within one or more cell lineages; (2) more than 
15% of ring sideroblasts; (3) cytogenetic abnormalities; and (4) mutations in the splicing factor SF3B1 in 
combination with > 5% ring sideroblasts[43-45]. 
LB 
Biopsies are medical procedures that involve taking a small sample of tissue to be examined and evaluated, 
and they have been used by clinicians to diagnose and manage diseases for more than 1000 years[46]. In 
cancer patients, biopsies are critical for the full histopathological characterization and staging of the 
disease, and they may also provide material for the characterization of the genetic profile of the tumor, 
which is key in enabling the projection of disease progression and the response to therapy[47]. Despite 
current advances in cancer diagnosis and treatment, traditional biopsies require invasive procedures 
(e.g., surgery), which may have potential complications, sometimes cannot be repeated for sampling, and 
are limited in use when the patients’ health status has decayed considerably or when the tumor is not 
accessible[48]. The genomic profile of biopsies provides a portrait of the cancer itself and of the considerable 
genetic heterogeneity of the several subclones that constitute the “tumor”, but they show a tremendous 
drawback: they are limited to assessing only a snapshot of the tumor rather than the whole dynamic 
process[49]. In fact, it has been widely recognized that the genome context of tumors (and their metastasis) 
show a dynamic development in time, frequently as a response to the selective pressure of the surrounding 
(microenvironment) and/or of the challenging chemo- and radiotherapies (acquired resistance) that are 
used to tackle cancer development and that might trigger the evolution of diverse cell clones[48]. For these 
reasons, in recent years, there has been a strong focus on retrieving a more comprehensive overview of the 
disease by analyzing tumor material directly in blood[49].
Biopsies of peripheral blood are called LB and represent a novel and more comprehensive approach to 
obtain robust molecular information from the tumor[50]. Apoptotic and necrotic cancer cells release into 
the blood/lymph circulation plenty of circulating DNA fragments (circulating tumor DNA, ctDNA), 
together with a multitude of small vesicles, namely exosomes (EXOs), which are small vesicles released by 
cells that include proteins and nucleic acids[47-49,51]. In many situations, LB allow for imaging techniques 
and/or re-biopsy. Perhaps the biggest benefit of LB is that retrieving the critical sample fluid is much less 
invasive than their solid counterparts, or even some imaging approaches relying on the use of contrast 
agents[52]. Another advantage of using LB is the possibility of improved early diagnosis. In some advanced 
staged cancers, ctDNA may be detected in three out of four patients[53,54]. A strong case for LBs has been 
put forward by the European Society for Medical Oncology that has proposed to use LB to re-biopsy 
for assessing the genomic mutation status of Epidermal Growth Factor (EGFR) in patients[55,56], which is 
strongly associated to drug response and the development of drug resistance mechanisms for these types 
of drugs. However, the possibility to assess the molecular evolution of these malignancies makes LBs a 
valuable tool to screen and identify alterations associated to drug response and, more relevant, profiles 
correlating to the development of drug resistance.
In fact, it is not the case of LB versus solid biopsies, but rather the complementary information that might 
be retrieved by using a combination of these approaches. When used together, LB allows for a more 
comprehensive characterization of tumor heterogeneity, but with a less invasive procedure that decreases 
the eventual discomfort to the patient. As such, it is possible to retrieve more information on the dynamics 
of molecular changes of cancer cells[57], which is critical for the assessment of therapeutic follow-up. LB 
opens up new possibilities for clinical characterization of malignancies for: (1) clinical management of 
advanced stage cancers; (2) prognosis of response to therapeutics; (3) detection of recurrence; and (4) 
evaluation of tumor genomic evolution[47,57].
ctDNA
During their lifespan, cells may release portions of DNA via numerous normal and pathological 
mechanisms. In normal conditions, cell free DNA (cfDNA) that is release from cells undergoing apoptosis 
and/or necrosis is rapidly taken up by the immune system, i.e., tissue macrophages[58,59]. However, the 
phagocytosis system may be overwhelmed and, as a result, higher amounts of DNA fragments reach the 
bloodstream. This DNA degradation frequently occurs during apoptosis, resulting in fragmentation of 
chromatin into nucleosomes that originate cfDNA fragments of 180-200 base pairs (bp)[60]. Living tumor 
cells also release ctDNA into the bloodstream, which may then mediate further malignant transformation 
and metastasis[61].
However, differences exist between the length ctDNA and cfDNA fragments. For example, some human 
cancers present a ctDNA rich fraction encompassing fragments that are circa 20-50 bp shorter than that 
of cfDNA of healthy donors[62]. ctDNA has several molecular characteristics associated with the tumor of 
origin, such as mutation pattern, copy number variations (CNVs), and methylation level[63-67]. ctDNA is 
predominantly found in plasma and serum, but it has also been recovered from other body fluids, such as 
breast milk, bone marrow, etc.[68]. Generally, circulating nucleic acids show half-lives between 15 min and 
several hours before being removed from circulation by the liver and kidney[69,70].
One of the main concerns when analyzing cfDNA is the possibility of contamination by genomic DNA 
(e.g., that might be released from circulating blood cells or endothelia). This may be circumvented by using 
plasma rather than serum as LB for cfDNA analysis[71]. There have been several reports putting forward the 
use of other body fluids, such as urine[72], saliva[73], and cerebrospinal fluid[74], as a substitute for plasma as 
a source of sizeable amounts of ctDNA. In LB targeting cfDNA, it is recommended to use anticoagulants 
that may also act as nuclease inhibitors, such as ethylenediaminetetraacetic acid (EDTA). Caution should 
be paid to the fact that excess EDTA may hamper the efficiency of the downstream enzymatic reactions, 
such as those used in amplification protocols (e.g., polymerase chain reaction, PCR)[75]. The major drawback 
of using blood as LB is the presence of genomic DNA derived from circulating blood cells that would both 
affect concentration of cfDNA and introduce bias in terms of sequence analysis[76]. In addition, transport 
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and storage conditions affect cfDNA amounts, since non-optimal temperature and mechanical stress might 
induce cell lysis that release cfDNA into the collected sample[77]. 
The potential of cfDNA for cancer genetic profiling has been recognized since the end of World War 
II[78]. Some thirty years later, it was already accepted that cancer patients showed elevated levels of cfDNA 
in peripheral blood. The average cfDNA concentration is almost 400 times higher for cancer patients, 
when compared to the healthy individuals[79]. The highest levels were observed in patients with advanced 
metastatic disease resistant to chemotherapy and poor prognosis[79]. The relevance of cfDNA analysis in 
hematological malignancies was reinforced by showing that possibility to assess specific mutation status 
associated to malignancy, such as NRAS mutations in MDS and AML[80]. In 2013, the first report of cancer 
detection using cfDNA from a pregnant woman showed the correlation between the non-invasive prenatal 
testing suggestive of an aneuploidy for chromosomes 13 and 18 (that targets fetal cfDNA in maternal 
cfDNA) and a small cell carcinoma with aneuploidy in 80% of analyzed cells, including chromosomes 13 
and 18[81,82].
Currently, ctDNA analysis is used for both for direct diagnosis and to assess tumor progression, 
particularly useful to evaluate the molecular response to therapeutics. These analyses can be performed 
using both manual and automated systems able to extract ctDNA from plasma[83,84]. ctDNA has also 
been used to assess tumor burden and for multiplex analysis of gene mutations, including the customary 
biomarkers: EGFR, HER-2, BRAF, KRAS, ALK, and KIT[85]. Additionally, mounting evidence indicates 
that ctDNA is extremely useful for the identification of mutations associated to treatment options[83,86,87]. 
In addition, even CNVs, which may be difficult to analyze, have been successfully screened[85]. A recent 
approach has been reported to be used for the diagnostics of eight common cancer types through the 
assessment of mutations in cfDNA-CancerSEEK[88]. 
The growing knowledge that a particular tumor may evolve through the expansion of heterogenous 
genetically distinct subclones originating from sequence alterations has triggered the interest in assessing 
the frequency, identity, and molecular evolution of these clones. The difficulties in performing these analyses 
from traditional biopsies has redirected clinicians to use LB, with the possibility to follow the succession 
of occurring molecular events[89,90]. In fact, the evolutionary phylogenetic subclone analysis in non-small 
cell lung carcinoma (NSCLC) was possible via the utilization of ctDNA collected over 30 weeks[90]. From 
the reported data, it becomes clear that ctDNA may be used for the molecular analysis of subclones of a 
primary tumor that only exist in small sizes. In addition, the use of ctDNA also allowed characterizing 
metastatic subclones from the primary tumor that could be used as a specific tumor marker for evaluating 
response to in NSCLC[90,91].
 
Circulating tumor cells
The first description of the ability of cancer cells to travel through the bloodstream and metastasize in 
distant tissues and organs was reported in the late 19th century[92]. During the same period, several studies 
culminated in the discovery of circulating tumor cells (CTCs) that consisted of tumor cells circulating 
in the bloodstream whose characteristics strongly resemble those of an existing tumor[93]. It is generally 
accepted that CTCs may be shed from tumor sites, be it the primary tumor or secondary metastatic 
tissue, directly into circulation. Perhaps it is the relationship between CTCs’ tumorgenicity and their 
“traveling” capability that has made them a pivotal element in the processes leading to the development of 
metastases[94]. CTCs are nucleated cells originating in epithelia that make their way into the bloodstream 
and are found circulating in the in low numbers (less than 1 per 100 leukocytes)[95]. Depending on the 
tissue of origin, CTCs may present distinct morphological characteristics that vary according to cancer 
type and stage[94]. CTCs are usually found in clusters of tumor cells or associated to fibroblasts, leukocytes, 
and other endothelial cells, which increases the odds of colonizing distant tissues and originating 
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metastasis[96]. Almost every type of solid tumor has been shown to be capable of shedding CTCs to the 
bloodstream and, thus, turning these CTCs into valuable biomarkers of disease progression[97]. As such, 
tremendous effort has been directed towards the development of analytical systems able to detect and 
isolate CTCs from whole blood. The majority of these platforms rely on the presence/absence of specific 
markers at the cell surface, such as epithelial cell adhesion molecule (EpCAM+), cytokeratin 8 (CK8+), and 
cytokeratin 19 (CK19+), among others[98]. For example, using these biomarkers, it was possible to detect 
metastatic breast cancer, where a level of 6-7 CTCs per 10 mL of blood correlated to poor survival[99]. 
However, sometimes, CTCs do not exhibit robust EpCAM expression at the surface and, as such, other 
antibodies targeting distinct cell surface markers may be used for capture and isolation of CTCs[100]. 
Recent developments have simplified the procedures to retrieve CTCs from blood samples. For example, 
in 2007, Nagrath et al.[101] reported on a platform for capturing CTCs from whole blood via a microfluidic 
device, whose size might allow for point-of-care analysis. In the last years, there have been several attempts 
to develop integrated microfluidic devices for improved recovery of CTCs with higher purity by combining 
antibody assisted capture with size exclusion protocols[102]. For instance, a microfluidic chip for CTC 
isolation from blood-iChip-has been advertised that combines magnetic separation, hydrodynamic sorting, 
and inertial focusing of CTCs[103].
PCR based protocols have allowed amplification of epithelial cell specific markers after the synthesis of 
cDNA from total RNA isolated from viable CTCs[104,105]. Critical information for improving diagnostics 
and clinical characterization in cancer patients can be retrieved from the molecular characterization 
of CTCs, e.g., expression level of gene drivers and single-cell profiling[106-113]. Several other biomarkers 
originating from CTCs have been used for more robust molecular profiling of cancer cells, such as single 
or multiplexed panels of microRNAs (miRNAs)[114,115].
miRNA
miRNAs are small (19-24 bp) non-coding RNAs that play a critical role in post-transcriptional modulation 
of gene expression, whose role in cancer was elucidated at the beginning of the millennium[116-120]. The 
prognostic value of miRNAs in cancer has been highlighted in several studies. In 2005, Calin et al.[120] 
showed for the first time the relevance of miRNAs for diagnostic and the correlation to prognostic. 
Subsequently, it was demonstrated that miRNAs were transcribed from cancer-related regions associated 
to DNA amplification, deletion, or translocation[121]. Another example is let-7, which, when expressed at 
lower levels in lung cancer patients, correlates to poor survival[122]. These pioneering studies highlighted 
the role of miRNA in cancer development and the value of assessing their expression for diagnosis and its 
correlation to prognosis[123]. 
miRNAs are found in virtually all body f luids[124,125]. miRNAs are routinely detected in LB without 
noticeable changes in molecular and chemical stability[126-130]. In fact, miRNAs are extremely resilient to 
ribonucleases, which may be associated to their ability to bind plasma proteins, such as Argonaute 2 and 
high-density lipoprotein[131,132]. In addition, these miRNAs may be engulfed in secretory vesicles, including 
circulating exosomes and apoptotic bodies[128,133-135] (see below). Selected plasma/serum circulating 
miRNAs could be used to discriminate cancer patients (e.g., breast[136], colorectal[137], gastric[138], lung[139], 
pancreatic[140], and hepatocellular[141]) from healthy individuals, making them excellent tools for earlier 
diagnosis.
In 2007, Caivano et al.[142] showed that miRNA155 detected in from body fluids could be used as biomarker 
for the diagnostics and follow-up of hematologic malignancies through non-invasive biopsy approaches. 
Their results showed that miRNA155 levels in extracellular vesicles (EVs) were significantly higher in CLL, 
AML, and Waldenström’s macroglobulinemia patients. They also found that miRNA155 levels in EVs were 
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significantly lower in MDS and multiple myeloma. Moreover, high miRNA155 levels in EVs correlated to 
higher counts of white blood cell in AML patients.
Several approaches to analyze circulating miRNA levels have since emerged, including RT-qPCR, high-
throughput microarrays, and, more recently, deep next generation sequencing (NGS) protocols[143].
Exosomes
The intrinsic characteristics of exosomes make these vesicles suitable tumor biomarkers for LB. Exosomes 
are nanosized vesicles composed of a bi-lipidic membrane containing membrane proteins with a lumen 
composed of cytoplasmic proteins, RNAs, including mRNA and miRNAs, and others, such as cytokines or 
growth factors. Exosomes are formed in the endosomal pathway of eukaryotic cells and, thus, are highly 
enriched in proteins, such as tetraspanins, and adhesion molecules, such as integrins and cadherins[144]. 
Exosomes have an important role in cell-cell autocrine, paracrine, and endocrine communications and can 
be isolated from body fluids, such as plasma, urine, pericardial, pleural effusions, and amniotic fluid[145,146].
In the cancer context, tumor cell derived exosomes have an active role in tumor progression, therapy 
invasion, and metastasis formation[147-152]. As exosomes content depends on the physiological state of 
the cell, the cargo and abundance of tumor derived exosomes generally ref lects the stage of the tumor, 
rendering diagnostic value in LB for early tumor detection[153-155]. Even though exosomes are not being used 
in clinical practice, the potential of these vesicles for diagnosis is highlighted by the 71 clinical trials studies 
focused on exosomes of cancer patients (according to www.clinicalTrials.gov accessed on 12 September 
2019), accompanied by the development of platforms for tumor derived exosomes detection in complex 
samples (e.g., surface plasmon resonance for exosome biomarkers detection[156], microf luidic chip for 
ovarian cancer diagnosis[157], or a platform with superparamagnetic conjunctions and molecular beacons 
targeting urinary exosomes for prostate cancer diagnosis[158]). Nevertheless, several sensitive and specific 
exosomal biomarkers were already suggested for early diagnosis of ovarian cancer (over-expression of miR-
200a, miR-200b, and miR200c in patient’s serum exosomes)[159-161], non-small cell lung cancer (enrichment 
of Leucine-rich a2-glycoprotein 1 in exosomes of patients urine and MALAT-1 in patient’s blood)[162-164], 
colon cancer (overexpression of miR-1246 and miR-23a in patient’s serum exosomes)[165,166], or pancreatic 
ductal adenocarcinoma (presence of glypican-1 in patient’s serum)[167,168]. Regarding the metastatic potential 
of exosomes, it was described that presence of VEGF and PGF in exosomes could induce the initiation 
of the pre-metastatic niche at distant sites[169,170] and the presence of specific integrins in the membrane 
of exosomes dictate internalization by a specific cell type, predicting organ of metastasis, e.g., exosomes 
expressing ITGaVβ5 bind specifically to Kupfer cells, defining liver tropism
[171-173]. 
The interest in the role of exosomes in liquid malignancies has been gaining momentum. As for the 
solid tumors, exosomes play important roles in progression and therapy resistance of lymphoma and 
leukemia[174,175]. For example, in CML, exosomes are active players in neo-angiogenesis at the bone marrow, 
possibly through exosome pro-angiogenic miRNAs-miR-92 and miR-126[176-180]. The increase density and 
caliber of microvessels at the bone marrow of CML patients were suggested to be directly correlated with 
disease progression and poorer prognosis[181].
LB IN MYELOID MALIGNANCIES 
Conventional diagnostics of myeloid and/or lymphoid malignancies rely on full blood characterization 
with precise blood counts, complemented by morphologic examination of the bone marrow. Bone marrow 
aspirates are usually collected using a fine needle. Other samples include the removal of lymph node. 
All of these procedures are extremely disturbing for the patient since they are highly invasive[182]. Upon 
therapy, patient follow up requires a peripheral blood assessment every three months for morphological, 
cytogenetic, or molecular marker evaluation. The mounting evidence supporting the straightforward 
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correlation between blood and biopsies in hematological malignancies has challenged the need for invasive 
procedures to retrieve information that is accessible via LB[182]. The discovery of CTCs and ctDNA has 
paved the way for non-invasive monitoring techniques. In fact, a peripheral blood sample allows screening 
CTCs, ctDNA, cfDNA, miRNAs, and vesicles (e.g., exosomes)[182]. In the next sections, we focus on the 
advantages of LB for myeloid malignancy management. 
LB in AML
cfDNA mutational profiling in hematologic malignancies was performed for the first time in patients with 
AML and MDS[80]. Mutations in cfDNA were detected in 60% of patients, whereas these mutations were not 
present in DNA extracted from the respective paired peripheral blood or bone marrow. This fact reinforced 
the idea that plasma was an accessible and valuable material for diagnostics and monitoring of AML/
MDS[80]. More than 20 years later, it was revealed that blood of AML/MDS patients was enriched in tumor 
DNA[183]. Indeed, it is well known that cancer patients and, in particular AML patients, have elevated 
levels of cfDNA when compared to healthy individuals[184,185]. miRNAs seem to be a valuable biomarker in 
AML, since these small molecules are more abundant in the plasma from AML patients at diagnosis, when 
compared to healthy individuals. Interestingly, miRNA levels decrease after chemotherapy. 
Another interesting element is that AML patients undergoing induction chemotherapy showed a reduction 
in circulating nucleosomal DNA fragments, but, in patients with complete remission, an initial rise in the 
cfDNA level was observed between Days 2 and 4 after induction chemotherapy, possibly due to increased 
apoptosis in response to treatment[186]. 
A pilot study by Koutova et al.[187] in 2015 used plasma for characterization of miRNA signatures in 
AML patients (at diagnosis and in remission) that could be correlated to evolution following standard 
chemotherapy and before planned transplantation.
Analyzing cfDNA from peripheral blood and gDNA from bone marrow, it has also been demonstrated that 
Loss of Heterozygosity and chromosome X inactivation are the most frequent genetic abnormalities found 
in AML and MDS patients[183]. Data retrieved from this type of wide screening studies suggest that analysis 
of tumor derived cfDNA may replace bone marrow aspirated for screening genomic abnormalities.
In AML patients, cytogenetics is the starting point for full diagnostics characterization. Then, several gene 
markers have been used for the genetic molecular profiling. Nucleophosmin 1 (NPM1), Proto-oncogene 
C-KIT (C-KIT), CCAAT/enhancer binding protein alpha (CEBPA), and FMS related tyrosine kinase 3 
(FLT3) are used for prognosis and direct therapeutic decisions following initial induction chemotherapy[188]. 
NPM1 is the most commonly mutated gene in AML and is therefore a valuable biomarker of disease[189,190]. 
Quan et al.[189] used cfDNA from AML patients to analyze the number of copies and mutations in NPM1 
by qPCR and NGS, respectively. The mutation profile of NPM1 correlated directly with different subtypes 
of AML. Cytogenetic and particular molecular profiles found in cfDNA of patients with myeloid disorders 
seem to be suitable towards molecular profiling that provides the necessary information for optimized 
prognosis and treatment decisions.
Recently, Nakamura and co-workers demonstrated, for the first time, that non-invasive ctDNA screening 
was comparable to bone marrow analysis towards identification of patients at high risk for relapse in MDS 
and AML following allo-HSCT[191]. Additionally, this study also demonstrated that serum ctDNA may 
be used for assessing minimal residual disease in AML and MDS following allo-HSCT and, thus, may 
alleviate patients from frequent bone marrow punctures.
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LB in MDS
Bone marrow biopsy is the standard protocol for genetic and epigenetic characterization in MDS. 
However, this is a complicated procedure that is not always easy to perform and/or feasible[50]. In these 
situations, cfDNA would represent a better and less painful alternative to determine the tumor status, 
allowing for detection of genetic mutations and methylation status of CpG islands in MDS patients 
by pyrosequencing[192]. More recently, detection of specific mutations in cfDNA using PCR and direct 
sequencing of several loci was also achieved, demonstrating the wide range of application of cfDNA in 
MDS characterization[193]. Yeh et al.[194] evaluated cfDNA as a minimally invasive material for the genetic 
profiling of MDS patients using a panel of 55 genes previously demonstrated to be involved in cancer onset 
and development. These findings suggest that cfDNA can provide comparable molecular information to 
bone marrow biopsy, which might be extremely useful when bone marrow biopsy cannot be performed.
LB in CML
The use of LB has not been thoroughly explored in CML. Nonetheless, exosomes retrieved from blood 
of CML patients contain amphiregulin, an inducer of EGFR activation in stromal cells located in the 
bone marrow that might be used as biomarker[195]. In turn, stromal cells activated via EGFR increase 
the secretion of IL-8, which then stimulates the proliferation of CML cells[195]. As such, these molecular 
markers may be used to evaluate the different stages of tumor cell evolution. It must be noted that the 
majority of studies focusing on CML have been performed using CML cell lineages, i.e., cell models, and 
validation of data in real patient samples still needs to be performed. Nevertheless, it has been shown that 
exosomes secreted by CML cells play a critical role in the formation of new vessels, perhaps even have 
a pivotal responsibility for neo-angiogenesis in the bone marrow of CML patients[176-180,195,196], and thus 
could be useful as surrogate markers for disease evolution. Several key molecules thought to play a role 
in angiogenesis have been identified within exosomes derived from CML, such as the pro-angiogenic 
miRNA92 and miRNA126[176,179]. Moreover, it has been demonstrated that exosomes derived from K562 
cells are able to induce angiotube formation in human umbilical vein endothelial cells (HUVEC)[178]. In 
addition, exosomes secreted by LAMA84 CML cells induced expression of IL-8 in HUVEC[180]. Altogether, 
these preliminary efforts seem to indicate the value of exosomes retrieved from LB in diagnostics and 
prognostics in CML. 
THE NEXT STEP IN LB IN LEUKEMIA
The growing interest in LB as a less invasive approach to retrieve valuable molecular information of 
malignancies, and thus more convenient for patients, has prompted the development of multiple clinical 
trials to evaluate LB as prognostic and predictive biomarkers (https://clinicaltrials.gov/). Table 1 highlights 
some of the most relevant clinical trials evaluating the possible use of LB in myeloid malignancies. It 
should be noted that there are more than 220 currently ongoing clinical trials focusing on LB in all types 
of cancer, demonstrating the importance of LB in cancer management. 
Some of these clinical trials are directed at the critical points herein discussed. For example, iCARE 
(NCT03138395) focuses on the need to provide follow-up in patients undergoing chemotherapy. In fact, 
not achieving minimal residual disease following chemotherapy might be a critical predictor of refractory 
disease and seems to be associated with the death of 20% of AML and 80% of MDS patients. iCARE 
addresses an important issue that concerns the use of droplet digital PCR (ddPCR) for quantitative mutant 
allele frequency (MAF) in plasma for MDS and AML patients before, during, and after chemotherapy 
treatment. This approach may bring evidence of the important role of non-invasive means of monitorization 
in phase II and III clinical trials of new therapeutic agents, and cancer progression, providing clinicians with 
an opportunity to intervene before patients relapse. This clinical trial has been withdrawn based on the need 
of collecting specimens from a bank that will require approval of an additional protocol for institutional 
review board, which highlights the need for standardized sample collection protocols for LB. 
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Clinical trials UMIN000033003 and NCT01541800 address ctDNA and miRNAs in LB, respectively, 
as a mean of following relapse and prognosis in leukemia patients. For cfDNA, genome-wide copy 
number evaluation from plasma via shallow or low-coverage sequencing of cfDNA is scalable and cost-
effective[197-201] and has recently been shown to be highly prognostic[201].
LB show several advantages for cancer management strategies, such as: (1) minimally invasiveness; (2) 
better reproduction of the patients’ genetic mutations profile; (3) suitability as companion diagnostics; and 
(4) sample collection decreases the possibility of contamination with unwanted tissue/cells. Because LB 
is less invasive, it may be used more recurrently with less negative impact for patients than conventional 
biopsies[202]. Additionally, mounting evidence shows that LB deliver better portrait of the genomic 
context of the tumor through time, which may be of extreme valuable as companion diagnostics with 
the possibility to screen for the time dependence evolution of mutations[203]. LB further advantages over 
conventional tissue biopsies include the possibility of becoming a source of fresh tumor-derived material 
that are free from contamination (e.g., chemical preservatives)[203]. The application of LB to follow and 
assess solid tumors has been clearly demonstrated, whose advantages over tissue biopsies have been 
thoroughly documented. Newman and co-workers evaluated the performance of LBs as starting material 
for the screening of genomic mutations and evaluation of disease burden by quantifying cfDNA levels. 
The molecular data retrieved from these assessments were compared to whole body imaging screens via 
positron-emission tomography and computed tomography, which showed that lower levels of cfDNA in the 
plasma correlated with better clinical prognostics[204].
There are also some limitations to the widespread utilization of LB. It should be noted that LB might be 
less efficacious for detecting rare variants at very low frequency. In addition, LBs may be able to assess 
tumor heterogeneity and identify which clones dominate at a particular colonization site, but combining 
them with standard solid biopsies clearly improves the robustness of information. Because different 
clones at different sites will release ctDNA at distinct rates, LBs may introduce an undesired bias into the 
quantitative molecular characterization of the tumor evolution. For example, brain metastases usually 
release little to no ctDNA into circulation[53]. This is particularly relevant when considering the assessment 
of minimal disease and/or resistance of a few clonal cells to therapeutics, where extremely high sensitivity 
is usually desirable.
In addition, several studies have highlighted the differences in cfDNA levels derived from distinct tumor 
types and between body fluids used for analysis[205-207]. The amount of cfDNA derived from a particular 
tumor correlates with the cancer stage, degree of vascularization, metastatic potential, and apoptosis 
rate[206,208]. In some cases, tumor-derived cfDNA may be lower than 1% of the total circulating DNA, which 
may not allow for retrieving the full picture required for effective management of the patient in hand. In 
addition, identification and characterization of mutations requires extensive validation of processes and 
protocols so as to ensure clinically relevant data[205,207].
CONCLUSION 
Early detection of cancer is critical for improving the chances of therapeutic intervention and enhance the 
overall survival rates. Tumor detection is confirmed by traditional tissue biopsy. Due to their invasiveness, 
issue biopsies show potential harmful effects on the patient wellbeing with several complications, they 
are sometimes impossible to repeat over time, and, in some clinical conditions, they are impossible to 
obtain when the tumor is inaccessible. As such, oncologists have been focusing on cancer-derived material 
in the blood, which are easier to access and collect with less impact to the patient. LB relying on CTCs, 
ctDNA, miRNA, and EXOs are at the core of innovative approaches to retrieve relevant information on 
the molecular aspects of the tumor, offering a range of information that allows functional studies, and 
with the potential for diagnostics and management of myeloid malignancies, including MDS, AML, and 
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CML. Innovative technology platforms have allowed the combination of standard molecular profiling 
with LB into integrated systems for biomarker capture and analysis. However, CTCs, ctDNA, and EXOs 
are usually recovered in small concentrations from samples, negatively impacting the analytical output in 
terms of specificity and sensitivity. Current high-throughput platforms often provide data that are not easy 
to reproduce across laboratories, highlighting the need for standardization of procedures for collection and 
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